Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
Journal: The New England journal of medicine
Published: April 29, 2021
Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
Journal: The New England journal of medicine
Published: April 29, 2021
NHS England-funded CT fractional flow reserve in the era of the ISCHEMIA trial.
Journal: Clinical medicine (London, England)
Published: March 25, 2021
Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics.
Journal: American heart journal
Published: September 14, 2020
Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: April 21, 2020
Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: September 25, 2019
Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: May 19, 2017
Showing 1-7 of 7
Last Updated: 09/26/2026